Qinghai Spring Medicinal Resources Technology Co., Ltd.

Shanghai Stock Exchange 600381.SS

Qinghai Spring Medicinal Resources Technology Co., Ltd. Gross Profit Margin for the year ending December 31, 2023: 60.44%

Qinghai Spring Medicinal Resources Technology Co., Ltd. Gross Profit Margin is 60.44% for the year ending December 31, 2023, a 31.08% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was 46.11%, a 133.68% change year over year.
Qinghai Spring Medicinal Resources Technology Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was 19.73%, a 3.32% change year over year.
Qinghai Spring Medicinal Resources Technology Co., Ltd. Gross Profit Margin for the year ending December 31, 2020 was 19.10%, a -31.31% change year over year.
Qinghai Spring Medicinal Resources Technology Co., Ltd. Gross Profit Margin for the year ending December 31, 2019 was 27.81%, a -6.20% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Shanghai Stock Exchange: 600381.SS

Qinghai Spring Medicinal Resources Technology Co., Ltd.

CEO	Mr. Xuefeng Zhang
IPO Date	May 8, 2001
Location	China
Headquarters	Xining Eco and Techn Dev Zone
Employees	173
Sector	Materials
Industries Paper & Forest Products Biotechnology Pharmaceuticals

Description

Qinghai Spring Medicinal Resources Technology Co., Ltd. research and development, production, and sale of cordyceps products. It is also involved in the sale of beverages and aquatic products; advertising; and foreign investment business. The company was founded in 2003 and is based in Xining, China.

Key trends

Past 5 years